ParkinsonCanadaV1, PascalFrancis, Curation, bibRecord, 000244

Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications

Identifieur interne : 000244 ( PascalFrancis/Curation ); précédent : 000243; suivant : 000245

Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications

Auteurs : Frédéric Calon [Canada] ; Marc Morissette [Canada] ; Ali H. Rajput [Canada] ; Oleh Hornykiewicz [Canada, Autriche] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada]

Source :

Movement disorders [ 0885-3185 ] ; 2003.

RBID : Pascal:03-0238134

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Récepteur gabaergique, Autoradiographie, Dopamine, Transport biologique, Catécholamine, Dyskinésie, Lévodopa, Chimiothérapie, Antiparkinsonien, Mécanisme action, Traitement, Toxicité, Métabolisme, Homme.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Antiparkinson agent, Autoradiography, Biological transport, Catecholamine, Chemotherapy, Dopamine, Dyskinesia, Gabaergic receptor, Human, Levodopa, Mechanism of action, Metabolism, Parkinson disease, Toxicity, Treatment.

Abstract

Brain samples from 14 Parkinson's disease patients, 10 of whom developed motor complications (dyskinesias and/or wearing-off) on dopaminomimetic therapy, and 11 controls were analyzed. Striatal 3β-(4-¹²⁵I-iodophenyl)tropane-2β-carboxylic acid isopropyl ester ([¹²⁵I]RTI-121)-specific binding to dopamine transporter and concentration of dopamine were markedly decreased, but no association between level of denervation and development of motor complications was observed. The homovanillic acid/dopamine ratio of concentrations was higher in putamen of patients with wearing-off compared to those without. Striatal ³⁵S-labeled t-butylbicyclophosphorothionate ([³⁵S]TBPS) and [³H]flunitrazepam binding to GABA_A receptors were unchanged in patients with Parkinsons disease, whereas [¹²⁵I]CGP 64213 -specific binding to GABA_B receptors was decreased in the putamen and external segment of the globus pallidus of parkinsonian patients compared with controls. [³H]Flunitrazepam binding was increased in the putamen of patients with wearing-off compared to those without. [³⁵S]TBPS-specific binding was increased in the ventral internal globus pallidus of dyskinetic subjects. These data suggest altered dopamine metabolism and increased GABA_A receptors in the putamen related to the pathophysiology of wearing-off. The present results also suggest that an up-regulation of GABA_A receptors in the internal globus pallidus is linked to the pathogenesis of levodopa-induced dyskinesias.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 18`
A06				`@2 3`
A08	`01`	`1`	`ENG`	`@1 Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications`
A11	`01`	`1`		`@1 CALON (Frédéric)`
A11	`02`	`1`		`@1 MORISSETTE (Marc)`
A11	`03`	`1`		`@1 RAJPUT (Ali H.)`
A11	`04`	`1`		`@1 HORNYKIEWICZ (Oleh)`
A11	`05`	`1`		`@1 BEDARD (Paul J.)`
A11	`06`	`1`		`@1 DI PAOLO (Thérèse)`
A14	`01`			`@1 Molecular Endocrinology and Oncology Research Center, Laval University Medical Center (CHUL), and Faculty of Pharmacy, Laval University @2 Québec @3 CAN @Z 1 aut. @Z 2 aut. @Z 6 aut.`
A14	`02`			`@1 Division of Neurology, University of Saskatchewan, Royal University Hospital @2 Saskatoon @3 CAN @Z 3 aut. @Z 4 aut.`
A14	`03`			`@1 Institute for Brain Research, Faculty of Medicine, University of Vienna @2 Vienna @3 AUT @Z 4 aut.`
A14	`04`			`@1 Neuroscience Research Unit, Laval University Medical Center (CHUL), and Department of Medicine, Faculty of Medicine, Laval University @2 Québec @3 CAN @Z 5 aut.`
A20				`@1 241-253`
A21				`@1 2003`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000109859510020`
A44				`@0 0000 @1 © 2003 INIST-CNRS. All rights reserved.`
A45				`@0 85 ref.`
A47	`01`	`1`		`@0 03-0238134`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Brain samples from 14 Parkinson's disease patients, 10 of whom developed motor complications (dyskinesias and/or wearing-off) on dopaminomimetic therapy, and 11 controls were analyzed. Striatal 3β-(4-¹²⁵I-iodophenyl)tropane-2β-carboxylic acid isopropyl ester ([¹²⁵I]RTI-121)-specific binding to dopamine transporter and concentration of dopamine were markedly decreased, but no association between level of denervation and development of motor complications was observed. The homovanillic acid/dopamine ratio of concentrations was higher in putamen of patients with wearing-off compared to those without. Striatal ³⁵S-labeled t-butylbicyclophosphorothionate ([³⁵S]TBPS) and [³H]flunitrazepam binding to GABA_A receptors were unchanged in patients with Parkinsons disease, whereas [¹²⁵I]CGP 64213 -specific binding to GABA_B receptors was decreased in the putamen and external segment of the globus pallidus of parkinsonian patients compared with controls. [³H]Flunitrazepam binding was increased in the putamen of patients with wearing-off compared to those without. [³⁵S]TBPS-specific binding was increased in the ventral internal globus pallidus of dyskinetic subjects. These data suggest altered dopamine metabolism and increased GABA_A receptors in the putamen related to the pathophysiology of wearing-off. The present results also suggest that an up-regulation of GABA_A receptors in the internal globus pallidus is linked to the pathogenesis of levodopa-induced dyskinesias.
C02	`01`	`X`		`@0 002B02U01`
C03	`01`	`X`	`FRE`	`@0 Parkinson maladie @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @5 01`
C03	`02`	`X`	`FRE`	`@0 Récepteur gabaergique @5 04`
C03	`02`	`X`	`ENG`	`@0 Gabaergic receptor @5 04`
C03	`02`	`X`	`SPA`	`@0 Receptor gabaminérgico @5 04`
C03	`03`	`X`	`FRE`	`@0 Autoradiographie @5 05`
C03	`03`	`X`	`ENG`	`@0 Autoradiography @5 05`
C03	`03`	`X`	`SPA`	`@0 Autorradiografía @5 05`
C03	`04`	`X`	`FRE`	`@0 Dopamine @2 NK @2 FR @5 07`
C03	`04`	`X`	`ENG`	`@0 Dopamine @2 NK @2 FR @5 07`
C03	`04`	`X`	`SPA`	`@0 Dopamina @2 NK @2 FR @5 07`
C03	`05`	`X`	`FRE`	`@0 Transport biologique @5 08`
C03	`05`	`X`	`ENG`	`@0 Biological transport @5 08`
C03	`05`	`X`	`SPA`	`@0 Transporte biológico @5 08`
C03	`06`	`X`	`FRE`	`@0 Catécholamine @5 09`
C03	`06`	`X`	`ENG`	`@0 Catecholamine @5 09`
C03	`06`	`X`	`SPA`	`@0 Catecolamina @5 09`
C03	`07`	`X`	`FRE`	`@0 Dyskinésie @5 10`
C03	`07`	`X`	`ENG`	`@0 Dyskinesia @5 10`
C03	`07`	`X`	`SPA`	`@0 Disquinesia @5 10`
C03	`08`	`X`	`FRE`	`@0 Lévodopa @2 NK @2 FR @5 13`
C03	`08`	`X`	`ENG`	`@0 Levodopa @2 NK @2 FR @5 13`
C03	`08`	`X`	`SPA`	`@0 Levodopa @2 NK @2 FR @5 13`
C03	`09`	`X`	`FRE`	`@0 Chimiothérapie @5 14`
C03	`09`	`X`	`ENG`	`@0 Chemotherapy @5 14`
C03	`09`	`X`	`SPA`	`@0 Quimioterapia @5 14`
C03	`10`	`X`	`FRE`	`@0 Antiparkinsonien @5 15`
C03	`10`	`X`	`ENG`	`@0 Antiparkinson agent @5 15`
C03	`10`	`X`	`SPA`	`@0 Antiparkinsoniano @5 15`
C03	`11`	`X`	`FRE`	`@0 Mécanisme action @5 16`
C03	`11`	`X`	`ENG`	`@0 Mechanism of action @5 16`
C03	`11`	`X`	`SPA`	`@0 Mecanismo acción @5 16`
C03	`12`	`X`	`FRE`	`@0 Traitement @5 17`
C03	`12`	`X`	`ENG`	`@0 Treatment @5 17`
C03	`12`	`X`	`SPA`	`@0 Tratamiento @5 17`
C03	`13`	`X`	`FRE`	`@0 Toxicité @5 18`
C03	`13`	`X`	`ENG`	`@0 Toxicity @5 18`
C03	`13`	`X`	`SPA`	`@0 Toxicidad @5 18`
C03	`14`	`X`	`FRE`	`@0 Métabolisme @5 19`
C03	`14`	`X`	`ENG`	`@0 Metabolism @5 19`
C03	`14`	`X`	`SPA`	`@0 Metabolismo @5 19`
C03	`15`	`X`	`FRE`	`@0 Homme @5 20`
C03	`15`	`X`	`ENG`	`@0 Human @5 20`
C03	`15`	`X`	`SPA`	`@0 Hombre @5 20`
C07	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 37`
C07	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 38`
C07	`02`	`X`	`ENG`	`@0 Central nervous system disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 38`
C07	`03`	`X`	`FRE`	`@0 Encéphale pathologie @5 39`
C07	`03`	`X`	`ENG`	`@0 Cerebral disorder @5 39`
C07	`03`	`X`	`SPA`	`@0 Encéfalo patología @5 39`
C07	`04`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 40`
C07	`05`	`X`	`FRE`	`@0 Maladie dégénérative @5 41`
C07	`05`	`X`	`ENG`	`@0 Degenerative disease @5 41`
C07	`05`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 41`
C07	`06`	`X`	`FRE`	`@0 Mouvement involontaire @5 61`
C07	`06`	`X`	`ENG`	`@0 Involuntary movement @5 61`
C07	`06`	`X`	`SPA`	`@0 Movimiento involuntario @5 61`
C07	`07`	`X`	`FRE`	`@0 Trouble neurologique @5 62`
C07	`07`	`X`	`ENG`	`@0 Neurological disorder @5 62`
C07	`07`	`X`	`SPA`	`@0 Trastorno neurológico @5 62`
C07	`08`	`X`	`FRE`	`@0 Trouble moteur @5 63`
C07	`08`	`X`	`ENG`	`@0 Motor system disorder @5 63`
C07	`08`	`X`	`SPA`	`@0 Trastorno motor @5 63`
N21				`@1 146`
N82				`@1 PSI`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000A79

Links to Exploration step

Pascal:03-0238134

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications</title>
<author><name sortKey="Calon, Frederic" sort="Calon, Frederic" uniqKey="Calon F" first="Frédéric" last="Calon">Frédéric Calon</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Molecular Endocrinology and Oncology Research Center, Laval University Medical Center (CHUL), and Faculty of Pharmacy, Laval University</s1>
<s2>Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Morissette, Marc" sort="Morissette, Marc" uniqKey="Morissette M" first="Marc" last="Morissette">Marc Morissette</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Molecular Endocrinology and Oncology Research Center, Laval University Medical Center (CHUL), and Faculty of Pharmacy, Laval University</s1>
<s2>Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Rajput, Ali H" sort="Rajput, Ali H" uniqKey="Rajput A" first="Ali H." last="Rajput">Ali H. Rajput</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Neurology, University of Saskatchewan, Royal University Hospital</s1>
<s2>Saskatoon</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Hornykiewicz, Oleh" sort="Hornykiewicz, Oleh" uniqKey="Hornykiewicz O" first="Oleh" last="Hornykiewicz">Oleh Hornykiewicz</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Neurology, University of Saskatchewan, Royal University Hospital</s1>
<s2>Saskatoon</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Institute for Brain Research, Faculty of Medicine, University of Vienna</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Bedard, Paul J" sort="Bedard, Paul J" uniqKey="Bedard P" first="Paul J." last="Bedard">Paul J. Bedard</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Neuroscience Research Unit, Laval University Medical Center (CHUL), and Department of Medicine, Faculty of Medicine, Laval University</s1>
<s2>Québec</s2>
<s3>CAN</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thérèse" last="Di Paolo">Thérèse Di Paolo</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Molecular Endocrinology and Oncology Research Center, Laval University Medical Center (CHUL), and Faculty of Pharmacy, Laval University</s1>
<s2>Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">03-0238134</idno>
<date when="2003">2003</date>
<idno type="stanalyst">PASCAL 03-0238134 INIST</idno>
<idno type="RBID">Pascal:03-0238134</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000A79</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000244</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications</title>
<author><name sortKey="Calon, Frederic" sort="Calon, Frederic" uniqKey="Calon F" first="Frédéric" last="Calon">Frédéric Calon</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Molecular Endocrinology and Oncology Research Center, Laval University Medical Center (CHUL), and Faculty of Pharmacy, Laval University</s1>
<s2>Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Morissette, Marc" sort="Morissette, Marc" uniqKey="Morissette M" first="Marc" last="Morissette">Marc Morissette</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Molecular Endocrinology and Oncology Research Center, Laval University Medical Center (CHUL), and Faculty of Pharmacy, Laval University</s1>
<s2>Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Rajput, Ali H" sort="Rajput, Ali H" uniqKey="Rajput A" first="Ali H." last="Rajput">Ali H. Rajput</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Neurology, University of Saskatchewan, Royal University Hospital</s1>
<s2>Saskatoon</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Hornykiewicz, Oleh" sort="Hornykiewicz, Oleh" uniqKey="Hornykiewicz O" first="Oleh" last="Hornykiewicz">Oleh Hornykiewicz</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Neurology, University of Saskatchewan, Royal University Hospital</s1>
<s2>Saskatoon</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Institute for Brain Research, Faculty of Medicine, University of Vienna</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Bedard, Paul J" sort="Bedard, Paul J" uniqKey="Bedard P" first="Paul J." last="Bedard">Paul J. Bedard</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Neuroscience Research Unit, Laval University Medical Center (CHUL), and Department of Medicine, Faculty of Medicine, Laval University</s1>
<s2>Québec</s2>
<s3>CAN</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thérèse" last="Di Paolo">Thérèse Di Paolo</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Molecular Endocrinology and Oncology Research Center, Laval University Medical Center (CHUL), and Faculty of Pharmacy, Laval University</s1>
<s2>Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2003">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson agent</term>
<term>Autoradiography</term>
<term>Biological transport</term>
<term>Catecholamine</term>
<term>Chemotherapy</term>
<term>Dopamine</term>
<term>Dyskinesia</term>
<term>Gabaergic receptor</term>
<term>Human</term>
<term>Levodopa</term>
<term>Mechanism of action</term>
<term>Metabolism</term>
<term>Parkinson disease</term>
<term>Toxicity</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Récepteur gabaergique</term>
<term>Autoradiographie</term>
<term>Dopamine</term>
<term>Transport biologique</term>
<term>Catécholamine</term>
<term>Dyskinésie</term>
<term>Lévodopa</term>
<term>Chimiothérapie</term>
<term>Antiparkinsonien</term>
<term>Mécanisme action</term>
<term>Traitement</term>
<term>Toxicité</term>
<term>Métabolisme</term>
<term>Homme</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Brain samples from 14 Parkinson's disease patients, 10 of whom developed motor complications (dyskinesias and/or wearing-off) on dopaminomimetic therapy, and 11 controls were analyzed. Striatal 3β-(4-<sup>125</sup>
I-iodophenyl)tropane-2β-carboxylic acid isopropyl ester ([<sup>125</sup>
I]RTI-121)-specific binding to dopamine transporter and concentration of dopamine were markedly decreased, but no association between level of denervation and development of motor complications was observed. The homovanillic acid/dopamine ratio of concentrations was higher in putamen of patients with wearing-off compared to those without. Striatal <sup>35</sup>
S-labeled t-butylbicyclophosphorothionate ([<sup>35</sup>
S]TBPS) and [<sup>3</sup>
H]flunitrazepam binding to GABA<sub>A</sub>
 receptors were unchanged in patients with Parkinsons disease, whereas [<sup>125</sup>
I]CGP 64213 -specific binding to GABA<sub>B</sub>
 receptors was decreased in the putamen and external segment of the globus pallidus of parkinsonian patients compared with controls. [<sup>3</sup>
H]Flunitrazepam binding was increased in the putamen of patients with wearing-off compared to those without. [<sup>35</sup>
S]TBPS-specific binding was increased in the ventral internal globus pallidus of dyskinetic subjects. These data suggest altered dopamine metabolism and increased GABA<sub>A</sub>
 receptors in the putamen related to the pathophysiology of wearing-off. The present results also suggest that an up-regulation of GABA<sub>A</sub>
 receptors in the internal globus pallidus is linked to the pathogenesis of levodopa-induced dyskinesias.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>18</s2>
</fA05>
<fA06><s2>3</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>CALON (Frédéric)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>MORISSETTE (Marc)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>RAJPUT (Ali H.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>HORNYKIEWICZ (Oleh)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>BEDARD (Paul J.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>DI PAOLO (Thérèse)</s1>
</fA11>
<fA14 i1="01"><s1>Molecular Endocrinology and Oncology Research Center, Laval University Medical Center (CHUL), and Faculty of Pharmacy, Laval University</s1>
<s2>Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Division of Neurology, University of Saskatchewan, Royal University Hospital</s1>
<s2>Saskatoon</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Institute for Brain Research, Faculty of Medicine, University of Vienna</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Neuroscience Research Unit, Laval University Medical Center (CHUL), and Department of Medicine, Faculty of Medicine, Laval University</s1>
<s2>Québec</s2>
<s3>CAN</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA20><s1>241-253</s1>
</fA20>
<fA21><s1>2003</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000109859510020</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2003 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>85 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>03-0238134</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Brain samples from 14 Parkinson's disease patients, 10 of whom developed motor complications (dyskinesias and/or wearing-off) on dopaminomimetic therapy, and 11 controls were analyzed. Striatal 3β-(4-<sup>125</sup>
I-iodophenyl)tropane-2β-carboxylic acid isopropyl ester ([<sup>125</sup>
I]RTI-121)-specific binding to dopamine transporter and concentration of dopamine were markedly decreased, but no association between level of denervation and development of motor complications was observed. The homovanillic acid/dopamine ratio of concentrations was higher in putamen of patients with wearing-off compared to those without. Striatal <sup>35</sup>
S-labeled t-butylbicyclophosphorothionate ([<sup>35</sup>
S]TBPS) and [<sup>3</sup>
H]flunitrazepam binding to GABA<sub>A</sub>
 receptors were unchanged in patients with Parkinsons disease, whereas [<sup>125</sup>
I]CGP 64213 -specific binding to GABA<sub>B</sub>
 receptors was decreased in the putamen and external segment of the globus pallidus of parkinsonian patients compared with controls. [<sup>3</sup>
H]Flunitrazepam binding was increased in the putamen of patients with wearing-off compared to those without. [<sup>35</sup>
S]TBPS-specific binding was increased in the ventral internal globus pallidus of dyskinetic subjects. These data suggest altered dopamine metabolism and increased GABA<sub>A</sub>
 receptors in the putamen related to the pathophysiology of wearing-off. The present results also suggest that an up-regulation of GABA<sub>A</sub>
 receptors in the internal globus pallidus is linked to the pathogenesis of levodopa-induced dyskinesias.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02U01</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Récepteur gabaergique</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Gabaergic receptor</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Receptor gabaminérgico</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Autoradiographie</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Autoradiography</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Autorradiografía</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Dopamina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Transport biologique</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Biological transport</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Transporte biológico</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Catécholamine</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Catecholamine</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Catecolamina</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Dyskinésie</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Dyskinesia</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Disquinesia</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Lévodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>14</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>14</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>14</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
<s5>15</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
<s5>15</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
<s5>15</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Mécanisme action</s0>
<s5>16</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Mechanism of action</s0>
<s5>16</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Mecanismo acción</s0>
<s5>16</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Traitement</s0>
<s5>17</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Treatment</s0>
<s5>17</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>17</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Toxicité</s0>
<s5>18</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Toxicity</s0>
<s5>18</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Toxicidad</s0>
<s5>18</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Métabolisme</s0>
<s5>19</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Metabolism</s0>
<s5>19</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Metabolismo</s0>
<s5>19</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Mouvement involontaire</s0>
<s5>61</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Involuntary movement</s0>
<s5>61</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Movimiento involuntario</s0>
<s5>61</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>62</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>62</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>62</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Trouble moteur</s0>
<s5>63</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Motor system disorder</s0>
<s5>63</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Trastorno motor</s0>
<s5>63</s5>
</fC07>
<fN21><s1>146</s1>
</fN21>
<fN82><s1>PSI</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000244 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000244 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:03-0238134
   |texte=   Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications

Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri